DiaMedica Therapeutics Inc.

NasdaqCM:DMAC Stock Report

Market Cap: US$317.4m

DiaMedica Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:DMAC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
27 Aug 25BuyUS$5,958,107Jan StahlbergIndividual1,000,000US$6.00
27 Aug 25BuyUS$662,477Jan StahlbergIndividual110,420US$6.00
22 Aug 25BuyUS$1,062,340Jan StahlbergIndividual179,067US$5.99
15 Aug 25BuyUS$2,207,253Jan StahlbergIndividual372,248US$6.00
23 Jul 25BuyUS$1,400,000Richard JacintoIndividual400,000US$3.50
23 Jul 25BuyUS$9,999,997Thomas von KochIndividual2,857,142US$3.50
23 Jul 25BuyUS$1,400,000Richard JacintoIndividual400,000US$3.50
23 Jul 25BuyUS$4,999,999Jan StahlbergIndividual1,428,571US$3.50
23 Jul 25BuyUS$9,999,997Thomas von KochIndividual2,857,142US$3.50
23 Jul 25BuyUS$5,400,000Jan StahlbergIndividual1,542,857US$3.50

Insider Trading Volume

Insider Buying: DMAC insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of DMAC?
Owner TypeNumber of SharesOwnership Percentage
Institutions11,738,74422.7%
General Public15,328,44329.7%
Individual Insiders24,621,72647.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.9%.

Top Shareholders

Top 25 shareholders own 68.53% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.2%
Thomas von Koch
8,383,577US$51.5m51.7%no data
15%
Jan Stahlberg
7,764,465US$47.7m48.7%no data
9.59%
Richard Jacinto
4,958,823US$30.4m8.77%no data
4.74%
Leon Cooperman
2,450,000US$15.0m0%no data
4.21%
Dialectic Capital Management, LP
2,173,529US$13.3m0%57.44%
3.19%
Omega Advisors, Inc.
1,650,000US$10.1m1.54%0.33%
2.97%
The Vanguard Group, Inc.
1,535,054US$9.4m13.6%no data
2.31%
BlackRock, Inc.
1,191,813US$7.3m1,020%no data
1.28%
Leon & Toby Cooperman Foundation, Endowment Arm
660,220US$4.1m0%100.0%
1.26%
Paragon Associates, Ltd.
650,000US$4.0m8.33%5.66%
1.22%
Geode Capital Management, LLC
630,148US$3.9m99.6%no data
1.17%
First Manhattan Co. LLC
606,435US$3.7m0%0.01%
1.02%
David Wambeke
527,114US$3.2m0%no data
0.74%
Bleichroeder LP
382,317US$2.3m0%0.5%
0.66%
R. Giuffre
339,893US$2.1m-4.03%no data
0.63%
Northern Trust Global Investments
324,538US$2.0m83.1%no data
0.49%
State Street Global Advisors, Inc.
251,948US$1.5m196%no data
0.46%
Morgan Stanley, Investment Banking and Brokerage Investments
236,272US$1.5m128%no data
0.38%
LPL Financial Corporation, Asset Management Arm
197,500US$1.2m27.2%no data
0.28%
Osaic Wealth, Inc. , Asset Management Arm
144,290US$885.9k375%no data
0.17%
Jacob Asset Management of New York LLC
85,730US$526.4k-4.46%0.56%
0.15%
Charles Schwab Investment Management, Inc.
79,553US$488.5k500%no data
0.13%
Thrivent Trust Company, Asset Management Arm
69,122US$424.4k0%0.01%
0.13%
Dietrich Pauls
68,591US$421.1k2.62%no data
0.12%
Marshall Wace LLP
61,719US$378.9k228%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/08 17:34
End of Day Share Price 2025/09/08 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DiaMedica Therapeutics Inc. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle BauserColliers Securities
Alexander NowakCraig-Hallum Capital Group LLC
Chase KnickerbockerCraig-Hallum Capital Group LLC